Advisor Resource Council Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Advisor Resource Council bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 9,202 shares of the biopharmaceutical company's stock, valued at approximately $995,000.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Venturi Wealth Management LLC lifted its position in Gilead Sciences by 78.0% during the 4th quarter. Venturi Wealth Management LLC now owns 2,658 shares of the biopharmaceutical company's stock worth $246,000 after acquiring an additional 1,165 shares during the period. Global Retirement Partners LLC lifted its holdings in shares of Gilead Sciences by 2.2% during the fourth quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company's stock worth $830,000 after purchasing an additional 194 shares during the period. Bell Bank lifted its holdings in shares of Gilead Sciences by 4.9% during the fourth quarter. Bell Bank now owns 118,187 shares of the biopharmaceutical company's stock worth $10,917,000 after purchasing an additional 5,546 shares during the period. Finally, Oxbow Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.6% during the fourth quarter. Oxbow Advisors LLC now owns 71,941 shares of the biopharmaceutical company's stock worth $6,645,000 after purchasing an additional 450 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on GILD shares. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,500 shares of company stock worth $5,236,245 over the last three months. Insiders own 0.27% of the company's stock.

Gilead Sciences Trading Up 0.5%

Gilead Sciences stock traded up $0.50 during midday trading on Friday, hitting $108.50. 23,266,621 shares of the stock were exchanged, compared to its average volume of 7,661,575. Gilead Sciences, Inc. has a fifty-two week low of $66.01 and a fifty-two week high of $119.96. The stock has a market capitalization of $134.97 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29. The stock's 50-day simple moving average is $106.16 and its 200 day simple moving average is $102.88. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.32) EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.